DelveInsight Business Research LLP

Don’t miss this big event of the year! Come and meet our expert Rajesh Sharma at ESMO - European Society for Medical Oncology 2024 conference and experience how DelveInsight Business Research LLP can help you with best-in-class intelligence and provide analysis with respect to the consultation goal to tackle the most relevant problems faced in the healthcare domain. For any query, reach out to us at info@delveinsight.com or schedule a meeting with us today: https://lnkd.in/gzTKqyRy #esmo #esmo2024 #esmoconference #oncology #consulting #businesssolutions #healthcare #pharmaceutical #pharma #lifesciences

DelveInsight’s analysis shows that the Friedreich's ataxia market in the 7MM is projected to grow significantly at a robust CAGR by 2034. Friedreich's ataxia, the most common form of hereditary ataxia in the United States, impacts approximately 1 in every 50,000 people. Leading companies such as PTC Therapeutics, Inc., Minoryx Therapeutics, Biogen, Lexeo Therapeutics, and Larimar Therapeutics Inc., are developing innovative therapies for Friedreich's ataxia. Key therapies like RT001, Vatiquinone, Leriglitazone, Omaveloxolone, LX2006, and CTI-1601 are expected to reshape the Friedreich's ataxia market in the upcoming years. Get more detailed insights:  https://lnkd.in/gzvetx99 #FriedreichsAtaxia #PharmaInnovation #DrugDevelopment #ClinicalTrials #DelveInsight

The global shortage of BCG has posed a major challenge for both healthcare providers and patients, especially those with non-muscle invasive bladder cancer (NMIBC). This issue came into focus in 2014 when Merck reported supply limitations for the TICE strain of BCG, marking the second shortage in three years; the first occurred when Sanofi announced a shortfall of its Connaught strain. After Sanofi exited the market in 2016, Merck became the primary global supplier. Despite these difficulties, the medical community is actively working to mitigate the shortage’s impact and ensure that patients receive appropriate treatment for BCG-unresponsive NMIBC. Merck has responded by significantly increasing its production capacity in recent years, now producing between 600,000 and 870,000 vials annually. During the worst of the shortage, BCG was prioritized for patients with carcinoma in situ (CIS) and high-grade non-muscle invasive urothelial cancers. The ongoing shortage highlights the urgent need for expanded production capacity, the creation of new BCG strains and alternative treatments, and collaborative approaches to managing limited resources. As pharmaceutical companies and research institutions continue to seek innovative solutions, there is optimism that this crisis may lead to more effective and accessible treatments for bladder cancer and other conditions dependent on BCG. Get more detailed insights on the BCG crisis bladder cancer treatment at https://lnkd.in/gdYusran

DelveInsight’s analysis indicates that North America is expected to lead the global peptide therapeutics market throughout the forecast period. In 2023, the gastrointestinal disorders segment held a significant revenue share within the peptide therapeutics market. Leading companies like AbbVie, AstraZeneca, GSK, Takeda, Novartis, Teva Pharmaceuticals Sanofi, Astellas Pharma, and others are actively advancing the development of peptide therapeutics. Get more detailed insights: https://lnkd.in/gj_6rZVn #PeptideTherapeutics #PharmaInnovation #DrugDevelopment #ClinicalTrials #DelveInsight

DelveInsight’s analysis indicates that the bacterial vaginosis market in the 7MM is projected to grow at a robust CAGR by 2034. In the United States, around 30% of women aged 14-49 are impacted, with the highest prevalence among non-white women. Leading companies like Osel, Siolta Therapeutics, and Gedea Biotech AB are developing innovative bacterial vaginosis therapies, including LACTIN-V, STMC-105, and pHyph, poised to reshape the market in the coming years. Get more detailed insights:  https://lnkd.in/g9wwJcd6 #BacterialVaginosis #PharmaInnovation #DrugDevelopment #ClinicalTrials #DelveInsight

DelveInsight’s analysis reveals that the cystic fibrosis market in the US was valued at approximately USD 7 billion in 2023. The number of diagnosed prevalent cases of cystic fibrosis in the US, currently around 33,000, is projected to grow significantly with a robust CAGR through 2034. Leading companies advancing cystic fibrosis treatment include Laurent Pharmaceuticals, Vertex Pharmaceuticals, SpliSense, Krystal Biotech, Inc., Aridis Pharmaceuticals, 4D Molecular Therapeutics, Sound Pharmaceuticals, Inc., Clarametyx Biosciences, and others. These innovators are developing cutting-edge therapies expected to reshape the cystic fibrosis market in the upcoming years. Key therapies under development include Ensifentrine, LAU-7b, Vanzacaftor/tezacaftor/deutivacaftor, SPL84, KB407, AR-501, 4D-710, SPI-1005, CMTX-101, BX004-A, BI 1291583, RSP-1502, ANG003, and others. Get more detailed insights: https://lnkd.in/gyeYs5dR #CysticFibrosis #PharmaInnovation #DrugDevelopment #ClinicalTrials #DelveInsight

DelveInsight’s pipeline report on metastatic prostate cancer reveals a dynamic and competitive landscape, with 75+ active players developing 80+ pipeline therapies for this challenging condition. Prominent companies leading the charge include AstraZeneca, Cardiff Oncology, Oncternal Therapeutics, Valerio Therapeutics, ORIC Pharmaceuticals Inc., Astellas Pharma, MediLink Therapeutics, Sagimet Biosciences, and others. Noteworthy therapies in the metastatic prostate cancer pipeline include Saruparib, Onvansertib, ONCT-534, VIO-01, ORIC-944, ZEN003694, YL201, TVB-2640, RO7656594, REGN5678, PF-07248144,, among others, each advancing through various stages of clinical trials. For more detailed insights:  https://lnkd.in/g-Qmf_iA #MetastaticProstateCancer #Oncology #PharmaInnovation #ClinicalTrials #DelveInsight #MarketAnalysis #DrugDevelopment

Don’t miss the big event of the year! Come and join our expert Rajesh Sharma at ESMO - European Society for Medical Oncology and experience how DelveInsight Business Research LLP can help you with best-in-class intelligence and provide analysis with respect to the consultation goal to tackle the most relevant problems faced in the healthcare domain. For any query, reach out at info@delveinsight.com or schedule a meeting with us today. For more information, visit: https://lnkd.in/giT7zdb3

Hypophosphatasia is a genetic metabolic disorder characterized by low levels of serum alkaline phosphatase (hypophosphatasemia) due to loss-of-function mutations in the ALPL gene, which codes for tissue-nonspecific alkaline phosphatase (TNSALP). According to DelveInsight Business Research LLP, in 2023, there were around 6,200 diagnosed cases of this ultra-rare disease across the 7MM, with nearly 85% of these cases being less severe. The severity of the disease can vary depending on genetic and environmental factors. In the past, drug development for rare or ultra-rare diseases was seen as unfeasible due to the small patient population. However, this view has changed recently, with some therapies for rare diseases, such as AstraZeneca’s STRENSIQ, becoming highly successful, generating over $1 billion in revenue. In 2023, STRENSIQ alone achieved $1.1 billion in sales, representing more than 20% growth compared to the previous year. DelveInsight estimates that the total market size for hypophosphatasia in the 7MM was nearly $1 billion in 2023, and it is expected to grow at a CAGR of 7.2% from 2024 to 2034. This growth is anticipated to be driven by the introduction of new therapies, such as AstraZeneca’s ALXN1850 (efzimfotase alfa), AM-Pharma’s Ilofotase alfa, and others, and increased disease awareness. To get more analysis on the hypophosphatasia market growth opportunities, visit https://lnkd.in/gN5cXzzZ

DelveInsight’s analysis reveals that the pancreatic cancer market across the 7MM was valued at approximately USD 1.6 billion in 2020. By 2023, the U.S. alone recorded around 64,000 new cases of pancreatic cancer, with numbers projected to rise during the forecast period from 2024 to 2034. Leading companies in the pancreatic cancer domain, such as FibroGen, Inc., OSE Immunotherapeutics, Lokon Pharma AB, Oncotelic, Helix BioPharma, Tvardi Therapeutics, AIM ImmunoTech, BioNTech SE, Prestige Biopharma Group (Prestige Biopharma / Prestige Biologics), HCW Biologics, Cantex Pharmaceuticals, Inc., XBiotech USA, Inc., Lumicell, CARsgen Therapeutics, and Panbela Therapeutics, Inc Therapeutics, are pioneering innovative therapies. Some of the key therapies for pancreatic cancer treatment include Pamrevlumab, OSE2101, LOAd703, OT-101, L-DOS47 + Doxorubicin, TTI-101, Rintatolimod, BNT122, PBP1510, HCW9218, Azeliragon, XB2001, LUM015, CT041, SBP-101, and others. Get detailed insights here: https://lnkd.in/gbdgEWDt #PancreaticCancer #Oncology #PharmaInnovation #ClinicalTrials #DelveInsight #MarketAnalysis #DrugDevelopment